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lrimawi@science.aAbstract A simple, precise, accurate, and stability-indicating method is developed and validated
for analysis of tetrahydrozoline hydrochloride in eye drop formulations. Separation was achieved
on a reversed-phase C8 column (125 mm 4.6 mm i.d., 5 mm) using a mobile phase consisting of
acetonitrile/phosphate buffer of pH 3.0 (20:80, v/v) at a ﬂow rate of 1.0 mL/min and UV detection
at 240 nm. This method is validated according to United States Pharmacopeia requirements for
new methods, which include accuracy, precision, selectivity, robustness, and linearity and range.
This method shows enough selectivity, accuracy, precision, and linearity and range to satisfy
Federal Drug Administration/International Conference on Harmonization regulatory require-
ments. The current method demonstrates good linearity over the range of 0.025–0.075 mg/mL of
tetrahydrozoline with r2 0.999. The average recovery of the method is 100.8% with a relative
standard deviation of 0.47%. The degree of reproducibility of the results obtained as a result of
small deliberate variations in the method parameters and by changing analytical operators has
proven that the method is robust and rugged.
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Tetrahydrozoline is a derivative of imidazoline, it is an alpha
agonist and its main mechanism of action is the constriction of
conjunctival blood vessels. This serves to relieve the redness of
the eye caused by minor ocular irritants. Tetrahydrozoline is
used in eye and nasal drop formulations. Its structure is shown
in Fig. 1.
The United States Pharmacopeia method for tetrahydrozoline
analysis as raw material and in nasal and ophthalmic solutions is
UV–vis spectrophotometry [1], which cannot detect impurities,
degradation products, excipients, or preservatives present in the
Figure 1 Structure of tetrahydrozoline hydrochloride.
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for tetrahydrozoline raw material analysis is titration with
perchloric acid [2], while pharmaceutical formulations of tetra-
hydrozoline are not included in the British Pharmacopeia.
Formulations of tetrahydrozoline hydrochloride may contain
preservatives e.g. benzalkonium hydrochloride that absorb in the
same UV-region of tetrahydrozoline. Thus, UV–vis spectro-
photometry cannot be used as selective and stability-indicating
method for tetrahydrozoline analysis in these formulations. In
this respect, a stability-indicating HPLC method is required for
the analysis of tetrahydrozoline in pharmaceutical formulations
(nasal and eye drops). Tetrahydrozoline hydrochloride was
determined by HPLC in RP-mode [3] and in reversed-phase
ion pair mode [4]. Tetrahydrozoline hydrochloride was also
determined in combination with other ingredients: ﬂuorometho-
lone [5], oﬂoxacin and prednisolone acetate [6], antazoline [7],
naphazoline [8], and in combination of its decomposition
products [9]. The current work presents a reversed phase and
stability-indicating method for analysis of tetrahydrozoline
hydrochloride in eye drop formulations. The method is simple
where reversed-phase-LC with isocratic elution and UV detec-
tion was used. Validation of the method was performed accord-
ing to the requirements of United States Pharmacopeia for assay
determination, which includes accuracy, precision (repeatability
and intermediate precision (ruggedness)), selectivity, robustness,
and linearity and range. Additionally, in order to meet the
regulatory guidance of the Federal Drug Administration/Inter-
national Conference on Harmonization (ICH) [10], tetrahydro-
zoline hydrochloride was degraded forcibly in acidic, basic, and
strong oxidizing agent solutions.2. Experimental
2.1. Chemicals
Acetonitrile HPLC grade was from J.T. Baker (NJ, USA).
Potassium dihydrogen phosphate, triethylamine, phosphoric
acid, hydrochloric acid, sodium hydroxide, and hydrogen
peroxide were from Merck (Darmstadt, Germany). Tetrahy-
drozoline hydrochloride RS was from United States Pharma-
copeia (Rockville, MD, USA).
2.2. Apparatus
HPLC system (Dionex system, USA) with a detector (PDA-
3000, 08011275), equipped with a pump (LPG-3400A, 8007455),
autosampler (WPS-300SL analytical 8008961), column compart-
ment (TCC-3000, 8008864), and solvent rack (SR-3000) was
employed during this study. The Chromeleon software was
employed. The chromatographic analysis was performed on C8column (125 mm 4.6 mm i.d., 5 mm) (Waters Corporation,
Milford, Massachusetts, USA).
2.3. Standard solutions and HPLC conditions
Phosphate buffer was prepared by dissolving 1.0 g of potas-
sium dihydrogen phosphate in 1000 mL of water, adding 3 mL
of triethylamine, and adjusting the pH to 3.0 with dilute
phosphoric acid solution. Diluent was prepared by adding
0.5 mL of phosphoric acid to 1000 mL of water. Filtered and
degassed mixtures of acetonitrile and buffer (different volume
fractions) were tested as mobile phases for tetrahydrozoline
hydrochloride analysis. Different ﬂow rates (1.0, 1.5, and
2.0 mL/min) were also tested. UV detection was performed
at 240 nm and injection volume was 20 mL.
Stock standard solution of tetrahydrozoline was prepared
by dissolving a quantity of tetrahydrozoline hydrochloride
equivalent to 100.0 mg of tetrahydrozoline in 100.0 mL of
diluent to obtain a solution having a known concentration of
1.0 mg/mL tetrahydrozoline.
Nominal (working) standard solution was prepared by
diluting 5 mL of stock standard solution to 100 mL diluent to
obtain a solution having a known concentration of 0.05 mg/mL
tetrahydrozoline.
Nominal solutions of the formulated tetrahydrozoline eye
drops were prepared by mixing a volume of the eye drops
(5.0 mL) equivalent to 2.5 mg of tetrahydrozoline in 50 mL of
diluent.3. Results and discussion
3.1. Method development
Preliminary studies involved trying C8 and C18 reversed-phase
columns and testing several mobile phase compositions were
conducted for the separation of tetrahydrozoline hydrochlor-
ide with good chromatographic parameters (e.g. minimized
peak tailing and good symmetry). A C8 column (5 mm,
125 mm 4.6 mm i.d.) as a stationary phase with a mobile
phase of acetonitrile/phosphate buffer pH 3.0 (20:80, v/v) at a
ﬂow rate of 1.0 mL/min and a detection wavelength of 240 nm
afforded the best separation of tetrahydrozoline.
3.2. Method validation
After method development, validation of the current test
method for tetrahydrozoline hydrochloride was performed in
accordance with United States Pharmacopeia requirements
for assay determination (category-I: analytical methods for quan-
titation of active ingredients in ﬁnished pharmaceutical products)
which include accuracy, precision, selectivity, robustness, and
linearity and range [10–14].
3.2.1. Linearity and range
To evaluate linearity of the method, ﬁve calibration standards
of tetrahydrozoline containing 0.025, 0.0375, 0.05, 0.0625, and
0.075 mg/mL were analyzed. A plot of peak areas versus
tetrahydrozoline concentration was linear in the range from
0.025 to 0.075 mg/mL of tetrahydrozoline with a correlation
coefﬁcient of 0.999. This result demonstrates linearity of this
method over the speciﬁed range.
Table 2 Robustness testing of the tetrahydrozoline.
Parameter Content of tetrahydrozoline assay (%) RSD
(%)
Sample 1 Sample 2 Sample 3 Mean
Flow rate (mL/min)
0.8 101.2 101.6 101.4 101.4
1.0 100.3 100.6 100.1 100.3 0.67
1.2 99.7 100.8 99.9 100.1
Acetonitrile (%)
18 101.1 100.2 100.7 100.7
20 99.8 101.1 100.9 100.6 0.70
22 99.1 100.1 99.7 99.6
Wavelength (nm)
235 99.8 101.1 100.8 100.6
240 100.3 101.1 100.6 100.7 0.52
245 101.6 100.7 101.0 101.1
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Figure 2 Chromatogram of tetrahydrozoline in eye drop for-
mulation. Mobile phase: acetonitrile/potassium dihydrogen phos-
phate buffer—pH 3.0 (20:80, v/v), ﬂow rate—1.0 mL/min,
injection volume—20 mL. Column: C8, 5 mm and 12.5 cm—length,
4.6 mm—inner diameter, UV detection: 240 nm. Peak asymmetry
and theoretical plates of tetrahydrozoline peak are 0.98 and 3100,
respectively.
HPLC method for tetrahydrozoline analysis 693.2.2. Accuracy and percentage recovery
Accuracy of the method was studied by preparing the placebo
of the drug formulation according to the formulation proce-
dure. To the required quantity of placebo, a known quantity
of tetrahydrozoline with the same proportion as in the drug
formulation was added to get three concentrations (0.025,
0.050, and 0.075 mg/mL of tetrahydrozoline). Results
have shown that the recovery of tetrahydrozoline is within
99.8.0–101.3%, and the RSD is lower than 1.0% (Table 1).
3.2.3. Precision
3.2.3.1. Repeatability. Repeatability of the method was eval-
uated by calculating the RSD of the peak areas of six replicate
injections for the standard concentration (100%) of tetrahy-
drazoline, which was found to be 0.27%. Furthermore, the
RSD of the peak areas of the recovery data analyzed in
accuracy study (see Section 3.2.2) for each level was calcu-
lated, and it was found to be less than 1.0% for each level
(0.35%, 0.26%, and 0.62% for 50%, 100%, and 150%,
respectively), as shown in Table 1. These results show that
the current method for tetrahydrozoline analysis is repeatable.
3.2.3.2. Intermediate precision (ruggedness). Intermediate
precision (also called ruggedness) of the method was also
evaluated by analyzing six samples of tetrahydrozoline by two
analysts in the same laboratory using different HPLC systems.
Results of this study showed that the RSD of the percentage
of tetrahydrazoline in tetrahydrazoline eye drops for the 12
samples (6 samples from each analyst) was 0.9% indicating a
good intermediate precision of the method.
3.2.4. Selectivity (stability indicating evaluation)
Selectivity of the method was demonstrated by enhancing degra-
dation of tetrahydrazoline under stress conditions (acid and base
hydrolysis and oxidation), to show that tetrahydrazoline is
separated from possible degradation products of tetrahydrozoline
resulted from stress condition. Results have shown that tetrahy-
drozoline is stable in hydrogen peroxide solution (it gives no
degradation products). Furthermore, it was found that tetrahy-
drozoline was stable when standard solution of it was stored at
room temperature or in oven at 60 1C for one week. On the other
hand, tetrahydrozoline was not stable in acidic and basic solutions;
about 40% and 35% of tetrahydrozoline was degraded in
hydrochloric acid solution and sodium hydroxide solution,
respectively. However, no degradation products were detected.
3.2.5. Robustness
Robustness of the current method was investigated by analyz-
ing three samples of tetrahydrozoline in eye drop formulationsTable 1 Accuracy (% recovery) of tetrahydrozoline in
eye drop formulation at three concentration levels.
Tetrahydrozoline
concentration
(mg/mL)
Accuracy (% recovery) RSD
(%)
Sample 1 Sample 2 Sample 3 Mean
0.025 100.9 101.3 100.6 100.9 0.35
0.050 101.1 101.0 100.6 100.9 0.26
0.075 99.8 100.7 101.0 100.5 0.62using the same chromatographic conditions set forth in method
development but (a) using ﬂow rate 0.8 and 1.2 mL/min instead
of 1.0 mL/min; (b) detection wavelength 235 and 245 nm instead
of 240 nm, and (c) volume fraction of acetonitrile is 18% and
22% instead of 20%. RSD of the percentage of tetrahydrozoline
under these conditions is calculated to be less than 1% (Table 2).
After successful development and validation of this method,
it was employed for analysis of tetrahydrozoline in eye drop
formulations as shown in Fig. 2.4. Conclusion
A simple, accurate, precise, and stability-indicating HPLC
method was developed and validated for the routine analysis
of tetrahydrozoline in eye drop formulations. The results
F. Al-Rimawi et al.70of stress testing undertaken according to the International
Conference on Harmonization guidelines reveal that the
method is selective and stability-indicating.Conﬂict of interest statement
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